MYKACET
Clinical safety rating
cautionComprehensive clinical and safety monograph for MYKACET (MYKACET).
MYKACET (acetaminophen) is a centrally acting analgesic and antipyretic. Its exact mechanism is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) isoenzymes in the central nervous system, particularly COX-2, and modulation of descending serotonergic pathways.
| Metabolism | Acetaminophen is extensively metabolized in the liver via conjugation with glucuronic acid (glucuronidation) and sulfuric acid (sulfation). A minor metabolite (N-acetyl-p-benzoquinone imine, NAPQI) is formed via cytochrome P450 isoenzymes (CYP2E1, CYP1A2, CYP3A4) and is primarily detoxified by conjugation with glutathione. |
| Excretion | Primarily renal excretion of unchanged drug via glomerular filtration and active tubular secretion; >90% of administered dose appears in urine within 24 hours; minimal biliary/fecal elimination (<5%). |
| Half-life | Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; extended to 12-24 hours in moderate to severe renal impairment (CrCl <30 mL/min), requiring dose adjustment. |
| Protein binding | Approximately 20-30% bound to serum proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid; does not extensively penetrate tissues or cross the blood-brain barrier. |
| Bioavailability | Oral bioavailability is approximately 50-70% due to first-pass metabolism; intravenous administration yields 100% bioavailability. |
| Onset of Action | Intravenous: Onset of action occurs within 30 minutes; oral: Onset within 1-2 hours. |
| Duration of Action | Duration of action is 6-8 hours for the intravenous route and 8-12 hours for the oral route, dependent on renal function and dosing interval. |
| Molecular Weight | 320.34 |
4 g intravenous every 8 hours over 3 hours, based on piperacillin 4 g and tazobactam 0.5 g.
| Dosage form | CREAM |
| Renal impairment | For CrCl 20-40 mL/min: 3 g (piperacillin 3 g / tazobactam 0.375 g) q8h; CrCl <20 mL/min: 2 g (piperacillin 2 g / tazobactam 0.25 g) q12h. |
| Liver impairment | No dose adjustment required for hepatic impairment; use standard dosing. |
| Pediatric use | For infants >2 months and children <40 kg: 100 mg/kg piperacillin component every 8 hours; for children ≥40 kg: adult dose (4 g q8h). |
| Geriatric use | Adjust dose based on renal function; no specific age-related adjustments beyond renal dosing. |
| 1st trimester | MYKACET (mycophenolic acid) is contraindicated in pregnancy due to increased risk of first-trimester pregnancy loss and congenital malformations. Women of childbearing potential must use effective contraception. |
| 2nd trimester | Contraindicated in second trimester. Associated with increased risk of spontaneous abortion and birth defects. |
| 3rd trimester | Contraindicated in third trimester. May cause neonatal leukopenia, thrombocytopenia, and infections. |
Clinical note
Comprehensive clinical and safety monograph for MYKACET (MYKACET).
| Placental transfer | Mycophenolic acid crosses the placenta. Animal studies show detectable fetal levels. Human data confirm placental transfer with fetal plasma levels approximately 30% of maternal levels. |
| Breastfeeding | Mycophenolic acid is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, including immunosuppression and hematologic toxicity, breastfeeding is not recommended during treatment. Manufacturers advise discontinuing drug or nursing. |
| Lactation Rating | Contraindicated (L5 - Hazardous) |
| Teratogenic Risk | MYKACET (acalabrutinib) is a BTK inhibitor. In animal studies, embryo-fetal toxicity was observed at maternal exposures below clinical doses. In pregnant women, no adequate data; however, based on mechanism of action, there is potential for fetal harm, particularly during organogenesis (first trimester). Avoid use in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor complete blood counts regularly due to risk of cytopenias. Assess hepatic and renal function. In pregnancy, perform fetal ultrasound monitoring for growth and anatomy if exposure occurs. Monitor for signs of infection or bleeding. |
| Fertility Effects | Animal studies indicate potential impairment of male and female fertility based on effects on reproductive organs at clinically relevant exposures. No human data; advise patients regarding potential risks to fertility. |
■ FDA Black Box Warning
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the maximum daily dose (4 grams/day).
| Serious Effects |
Hypersensitivity to mycophenolate or any componentPregnancy (women of childbearing potential not using reliable contraception)Women with childbearing potential not using effective contraceptionActive serious infections (e.g., tuberculosis, viral hepatitis)Live attenuated vaccines (contraindicated during therapy)
| Precautions | Hepatotoxicity: Risk of acute liver failure with doses exceeding 4g/day, in patients with pre-existing liver disease, or with chronic alcohol use., Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis can occur at any dose., Hypersensitivity reactions: Anaphylaxis and angioedema. |
| Food/Dietary | Grapefruit juice decreases mycophenolic acid exposure; avoid grapefruit products. High-fat meals reduce absorption; take on empty stomach. Cholestyramine reduces absorption; separate administration by at least 2 hours. Antacids containing magnesium or aluminum should be separated by 2 hours. |
| Clinical Pearls | Mykacet (mycophenolic acid) requires monitoring of complete blood counts due to risk of bone marrow suppression; dose adjustment needed in renal impairment. Avoid concomitant use with azathioprine; administer on empty stomach for consistent absorption. Levels may be affected by cholestyramine or antacids. |
| Patient Advice | Take capsules on an empty stomach, 1 hour before or 2 hours after meals. · Do not crush or chew capsules; swallow whole. · Avoid grapefruit juice and other grapefruit products during treatment. · Use effective contraception during and for 6 weeks after stopping therapy due to teratogenic risk. · Report any signs of infection (fever, sore throat) or unusual bruising/bleeding immediately. · Avoid live vaccines; discuss vaccination schedule with your doctor. · Take exactly as prescribed; do not stop without consulting your healthcare provider. |
Loading safety data…